Safety and Effectiveness Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

NCT00425321 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

259

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: RWJ-445380 100 mg
DRUG: RWJ-445380 200 mg
DRUG: RWJ-445380 300 mg
DRUG: Placebo

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.